secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0001558370-22-011768
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics Q2 cash $60.2M; FDA clears GMI-1687 IND; uproleselan Phase 3 data expected mid-2023
--------------------------------------------------------------------------------

- Cash and cash equivalents $60.2M as of June 30, 2022, down from $90.3M at Dec 31, 2021.
- R&D expenses $8.0M (down from $10.2M YoY) due to lower uproleselan trial costs after enrollment ended.
- G&A expenses $5.5M (up from $4.2M) for commercial start-up costs for uproleselan.
- FDA cleared IND for GMI-1687 in sickle cell disease; company seeks licensing partner.
- Phase 3 uproleselan trial (n=388) on track; survival events trigger expected mid-2023 with top-line data soon after.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837022011768/0001558370-22-011768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837022011768/glyc-20220803x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-011768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer